Disease Management
623 articles
The Promise of Organoids
Dr. Brian Wolpin explains how organoids are being used to develop personalized treatment for pancreatic cancer patients.
Adjuvant Chemotherapy with Modified FOLFIRINOX Regimen Improves Survival
A French clinical trial showed that adjuvant chemotherapy (given after surgery) with modified FOLFIRINOX improves survival of pancreatic cancer patients.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
Pancreatic Cancer Exceptional Responders and the Immune System Link
Dr. Vinod Balachandran looks at the immune system of exceptional responders–patients who respond extremely well to chemotherapy–for treatment clues.
Pancreatic Cancer Patients in the UK Benefit From Unique Precision Medicine Project
Dr. David Chang explains the Precision Panc initiative, a program through the UK’s NHS that helps pancreatic cancer patients find treatments.
What Happens When Pancreatic Cancer Clinical Trials Fail?
Why do clinical trials fail? What about the patients on the trial? Learn more about what happens when pancreatic cancer clinical trials fail.
The Future of Pancreatic Cancer Treatment
Dr. Anil Rustgi discusses the latest developments in pancreatic cancer treatment and the direction of current research in early detection.
Cachexia Research Gaining Momentum
Why do pancreatic cancer patients lose weight even if they are eating well? Dr. Teresa Zimmers explains the syndrome called cachexia.
RNA Precision Trial for Pancreatic Cancer Opens At Columbia
Dr. Andrea Califano leads a precision oncology clinical trial of the OncoTreat platform, which looks at proteins to determine treatment.
New Data Support Preoperative Chemoradiation Regimen for Borderline Resectable Pancreatic Cancer
Should patients get chemotherapy or chemoradiation before surgery? Dr. Matthew Katz provides an update on the Alliance study.
Reducing Pancreatic Cancer Risk Through Chemoprevention
Dr. Peter Allen leads a clinical trial of chemoprevention–the use of a medication to prevent IPMNs from developing into pancreatic cancer.
Targeting the Undruggable KRAS Protein
Dr. Shubham Pant is focusing his research on effective treatments for the KRAS mutation, found in 90% of pancreatic cancers.
The American Association for Cancer Research (AACR) Virtual Special Conference: Pancreatic Cancer Day Two
Let’s Win and the Lustgarten Foundation bring you the highlights from Day Two of the AACR special conference on pancreatic cancer.
New Clinical Accelerator Initiative Shortens Time from Bench to Clinic
Dr. Elizabeth Jaffee explains the importance of Lustgarten’s Clinical Accelerator Initiative to speed up the time from bench to trial.